APA (7th ed.) Citation

Han, H. S., Kim, W., Lee, Y., Won, C., Lee, W., Choi, S. Y., & Kim, B. J. Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19. MDPI AG.

Chicago Style (17th ed.) Citation

Han, Hye Sung, Won-Serk Kim, Yangwon Lee, Chong-Hyun Won, Wooshun Lee, Sun Young Choi, and Beom Joon Kim. Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19. MDPI AG.

MLA (9th ed.) Citation

Han, Hye Sung, et al. Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19. MDPI AG.